Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 ... | March 23, 2023

Related Keywords

United States ,Jenene Thomas ,Exchange Commission ,Clinical Program ,Palisade Bio Inc ,Globenewswire Inc ,Company Annual Report On Form ,Nasdaq ,Chief Executive ,Program Update ,Financial Results ,Year Ended ,Private Securities Litigation Reform Act ,Annual Report ,Convertible Preferred Stock ,Ended December ,Palisade Bio ,Nc Stock Exchange ,News ,Information ,Press Release ,Hase , ,Topline ,Data ,Readout ,Or ,Prevention ,F ,Prabdominal ,Adhesions ,N ,Track ,2 ,023 ,Strong ,Balance ,Sheet ,Ith ,Nsufficient ,Cash ,Xpected ,O ,Nto Pali Us6963892046 ,